Hutchmed Limited

GSK received FDA Breakthrough Therapy Designation for Jemperli (dostarlimab) to treat locally advanced dMMR/MSI-H rectal cancer, based on a phase II study showing a 100% clinical complete response rate in 42 patients. GSK's financial health score is 'GREAT', suggesting strong R&D investment potential. Dostarlimab aims to avoid standard treatment's long-term adverse effects, with ongoing studies to confirm findings and establish a new standard of care.

HUTCHMED to receive US$10M milestone payment from Takeda following European approval and Spain's first national reimbursement for FRUZAQLA® (fruquintinib), a novel oral targeted therapy for metastatic colorectal cancer.

HUTCHMED to receive $10 million milestone payment from Takeda following Spain's first national reimbursement for FRUZAQLA® (fruquintinib) in Dec 2024, marking the first European reimbursement for previously treated metastatic colorectal cancer. FRUZAQLA® received EU approval in June 2024 as the first novel oral targeted therapy for metastatic CRC regardless of biomarker status in over a decade.

China's NMPA granted breakthrough therapy designation to savolitinib and osimertinib for EGFR-mutant, MET-amplified NSCLC post-EGFR inhibitor therapy. The combination is being evaluated in the phase 3 SACHI trial vs platinum-doublet chemotherapy. Eligibility includes EGFR sensitizing mutations, MET amplification, and measurable lesions. The primary endpoint is investigator-assessed PFS, with secondary endpoints including overall survival and safety. The FDA also granted fast track designation to the combination in 2023.

HUTCHMED announces NMPA granted Breakthrough Therapy Designation to ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for EGFR mutation-positive NSCLC with MET amplification after EGFR inhibitor therapy. The combination is being evaluated in the Phase III SACHI trial in China.

HUTCHMED announces NMPA's Breakthrough Therapy Designation for ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) combo in EGFR mutation-positive NSCLC with MET amplification. The treatment is being evaluated in China's Phase III SACHI trial, comparing its efficacy and safety to standard platinum-based chemotherapy. NMPA grants BTD to therapies addressing life-threatening diseases with significant advantages over existing treatments, potentially expediting development and review.

AstraZeneca's Imfinzi approved in the US for limited-stage small cell lung cancer (LS-SCLC) after chemotherapy and radiation, based on ADRIATIC trial results showing improved survival and reduced risk of death and disease progression.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca, a global biopharmaceutical company, focuses on oncology, rare diseases, and bio-pharmaceuticals, aiming to redefine cancer care and eliminate it as a cause of death.

Subscribe to BioWorld™ news services.